GEN Exclusives

More »

GEN News Highlights

More »
Jan 13, 2011

CLC Bio Heads Consortium to Develop 1,000-Genome Analysis Software Suite

CLC Bio Heads Consortium to Develop 1,000-Genome Analysis Software Suite

Cogangs engine will enable new insights into interplay of gene-regulation factors. [© marc hericher - Fotolia.com]

  • CLC bio will head a €1.6 million (nearly $2.1 million) EU-funded comparative genomics consortium that aims to develop a software suite capable of analyzing up to a thousand genomes for gene-regulation analysis studies. The Cogangs (comparative genomics and next generation sequencing) project will also involve researchers at German firm Biobase, Iceland-based deCODE genetics, the Alfréd Rényi Institute of Mathematics in Hungary, BioRainbow in Russia, and the University of Oxford in the U.K.

    “We can potentially unlock a lot of information in the vast collection of human DNA samples we already have, once this project enables us to do large-scale comparative genomics analyses,” comments Gísli Másson, deCode’s director of bioinformatics. “We will apply both the initial prototype and the final software package for the analysis of regions that have been identified to have strong disease associations in the human genome.”

    Danish bioinformatics firm CLC bio claims to offer the only comprehensive cross-platform solution, capable of analyzing and visualizing genomic, transcriptomic, and epigenomic data from all major platforms, including Illumina’s Genome Analyzer, SOLiD by Applied Biosystems, Roche’s 454, and Helicos’ HeliScope.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?